Products Erenumab was approved in many countries, in the EU, and in the United States in 2018 as a solution for injection in a prefilled pen and a prefilled syringe (Aimovig, Novartis / Amgen). Structure and properties Erenumab is a human IgG2 monoclonal antibody directed against the CGRP receptor. It has a molecular weight of … Erenumab
Products Azacitidine is commercially available as a lyophilizate for the preparation of a suspension for injection (Vidaza, generic). It has been approved in many countries since 2006. Structure and properties Azacitidine (C8H12N4O5, Mr = 244.2 g/mol) is a derivative of the nucleoside cytidine found in nucleic acids. It belongs to the pyrimidine nucleoside analogues. Azacitidine … Azacitidine
Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Rituximab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for subcutaneous injection (MabThera, MabThera subcutaneous). It has been approved in many countries and in the United States since 1997 and in the EU since 1998. Biosimilars are available in some countries, including many (2018, Rixathon, … Rituximab
Products Enoxaparin is commercially available as a solution for injection (Clexane). It has been approved in many countries since 1988. Biosimilars were released in the EU in 2016 and in many countries in 2020 (Inhixa). Structure and properties Enoxaparin is present in the drug as enoxaparin sodium, the sodium salt of a low-molecular-weight heparin (LMWH) … Enoxaparin
Products Benralizumab was approved as a solution for injection in the United States in 2017 and in the EU and many countries in 2018 (Fasenra). Structure and properties Benralizumab is a humanized and afucosylated IgG1κ antibody with a molecular mass of 150 kDa. It is produced by biotechnological methods. Omission of the fucose in the … Benralizumab
Products The first agent in the GLP-1 receptor agonist group to be approved was exenatide (Byetta) in the United States in 2005 and in many countries and the EU in 2006. In the meantime, several other drugs have been registered (see below). These drugs are also known as incretin mimetics. They are commercially available as … GLP-1 Receptor Agonists
Symptoms The possible acute symptoms of type 1 diabetes include: Thirst (polydipsia) and hunger (polyphagia). Increased urination (polyuria). Visual disturbances Weight loss Fatigue, exhaustion, declining performance. Poor wound healing, infectious diseases. Skin lesions, itching Acute complications: Hyperacidity (ketoacidosis), coma, hyperosmolar hyperglycemic syndrome. The disease usually manifests in childhood or adolescence and is therefore also called … Diabetes Mellitus Type 1
Symptoms A dust mite allergy manifests itself in allergic symptoms. These include: Perennial allergic rhinitis: sneezing, runny nose, in the later course of the disease rather a chronically stuffy nose. Allergic conjunctivitis: itchy, watery, swollen and red eyes. Sinusitis with headache and facial pain Lower respiratory tract: cough, bronchial asthma. Itching, rash, eczema, exacerbation of … House Dust Mite Allergy
Products Evolocumab was approved in the EU and US in 2015 and in many countries in 2016 in the form of a solution for injection (Repatha). Structure and properties Evolocumab is a human IgG2 monoclonal antibody with a molecular mass of 141.8 kDa. It is produced by biotechnological methods. Effects Evolocumab (ATC C10AX13) has lipid-lowering … Evolocumab
Products Abatacept is commercially available as an injection and infusion preparation (Orencia). It was approved in the United States in 2005 and in the EU and many countries in 2007. Structure and properties Abatacept is a recombinant fusion protein with the following components: Extracellular domain of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Modified Fc domain of … Abatacept
Products Somatropin is commercially available as an injectable from several manufacturers. Recombinant growth hormone has been available since the late 1980s. Biosimilars are approved in some countries. Structure and properties Somatropin is a recombinant polypeptide hormone with a molecular mass of 22 kDa, consisting of 191 amino acids. It corresponds to human growth hormone from … Somatropin
